Enteropathy-associated T-cell lymphoma natural history, complications and prognosis: Difference between revisions
No edit summary |
No edit summary |
||
| Line 5: | Line 5: | ||
==Prognosis== | ==Prognosis== | ||
Recurrences most frequent in the small intestine<ref name=cancer.gov> Enteropathy-associated T-cell lymphoma. Surveillance, Epidemiology, and End Results Program. http://seer.cancer.gov/seertools/hemelymph/51f6cf56e3e27c3994bd5315/. Accessed on January 27, 2016</ref> | * Recurrences most frequent in the small intestine<ref name=cancer.gov> Enteropathy-associated T-cell lymphoma. Surveillance, Epidemiology, and End Results Program. http://seer.cancer.gov/seertools/hemelymph/51f6cf56e3e27c3994bd5315/. Accessed on January 27, 2016</ref> | ||
* According to the Peripheral T-Cell Lymphoma Project, median overall survival is ten months, while median failure-free survival is only six months | |||
* The peripheral index for T-cell lymphoma is useful in defining prognosis for enteropathy-associated T-cell lymphoma | |||
* Among the most influential prognostic factors is bulky disease, defined by a tumor mass greater than 5 cm<ref name="pmid21566094"/>. | |||
* [[Autologous stem cell transplantation]] is feasible for selected patients with enteropathy-associated T-cell lymphoma and can yield durable disease control in a significant proportion of these patients | |||
* One study found a trend for better survival in patients transplanted in first complete or partial remission at four years (66% vs. 36%; P = .062)<ref name="pmid23361910"/> | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 16:37, 27 January 2016
|
Enteropathy-associated T-cell lymphoma Microchapters |
|
Differentiating Enteropathy-associated T-cell lymphoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Enteropathy-associated T-cell lymphoma natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Enteropathy-associated T-cell lymphoma natural history, complications and prognosis |
|
FDA on Enteropathy-associated T-cell lymphoma natural history, complications and prognosis |
|
CDC on Enteropathy-associated T-cell lymphoma natural history, complications and prognosis |
|
Enteropathy-associated T-cell lymphoma natural history, complications and prognosis in the news |
|
Blogs on Enteropathy-associated T-cell lymphoma natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]
Overview
Prognosis
- Recurrences most frequent in the small intestine[1]
- According to the Peripheral T-Cell Lymphoma Project, median overall survival is ten months, while median failure-free survival is only six months
- The peripheral index for T-cell lymphoma is useful in defining prognosis for enteropathy-associated T-cell lymphoma
- Among the most influential prognostic factors is bulky disease, defined by a tumor mass greater than 5 cm[2].
- Autologous stem cell transplantation is feasible for selected patients with enteropathy-associated T-cell lymphoma and can yield durable disease control in a significant proportion of these patients
- One study found a trend for better survival in patients transplanted in first complete or partial remission at four years (66% vs. 36%; P = .062)[3]
References
- ↑ Enteropathy-associated T-cell lymphoma. Surveillance, Epidemiology, and End Results Program. http://seer.cancer.gov/seertools/hemelymph/51f6cf56e3e27c3994bd5315/. Accessed on January 27, 2016
- ↑
- ↑